Global Iron Deficiency Anaemia Treatment Market Report and Forecast 2024-2032

Global Iron Deficiency Anaemia Treatment Market Outlook

The iron deficiency anaemia treatment market size was valued at USD 4.5 billion in 2023. The market is likely to grow at a CAGR of 15.31% during the forecast period of 2024-2032 to attain a value of about USD 16.20 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Company News

In June 2021, a generic version of Feraheme was launched by Sandoz to treat patients with iron deficiency anaemia with Ferumoxytol, a high-dose intravenous iron supplement. The generic version of ferrahem (ferumoxytol injection), produced by AMAG Pharmaceuticals was approved to treat IDA in adults suffering from oral iron intolerance or chronic kidney disease, who do not respond well to oral iron.

In January 2020, the U.S. Food and Drug Administration (FDA) approved ferric derisomaltose injection, manufactured by PHARMACOSMOS A/S, for treating chronic kidney disease patients who cannot tolerate or are irresponsive to oral iron, or who are not dependent on haemodialysis for treating iron deficiency anaemia.

Introduction

A condition called anaemia occurs when the red blood cells (RBCs) or the haemoglobin concentration is insufficient. The body's tissues need haemoglobin to carry oxygen, and when a person has too few red blood cells, is malformed, or has no haemoglobin, then blood is unable to carry oxygen.

The main symptom of anaemia is a low number of red blood cells, which can cause paleness, fatigue, and weakness. The subtypes are classified according to the chronicity, size, and aetiology of the RBCs.

The loss of blood and decrease in red blood cell production can lead to anaemia due to an iron deficiency or an increase in red blood cell destruction by haemolysis. The main cause of anaemia is iron deficiency.

Iron levels can be used to categorize IDAs into mild, moderate, and severe categories. Symptoms and signs of mild to moderate disease are usually absent. Symptoms related to the severe form include fatigue, shortness of breath, or chest pain.

IDA (iron deficiency anaemia) is characterized by iron deficiency. This may be mainly due to low iron intake. IDA can also be caused by blood loss, an inability to absorb iron, and other health issues.

IDA is usually diagnosed by a physical exam and blood tests. In order to determine if the body has enough normal blood cells, iron and ferritin, a complete blood count is appropriate.

Treatment begins once IDA is diagnosed. Patients' characteristics and disease severity determine the treatment procedure. Increased consumption of iron supplements is the most common and the first prescribed treatment by doctors.

The supplements can be taken orally (Auryxia, Accrufer, and OTC) or intravenously (Venofer, Feraheme, and Monofer, among others). A blood transfusion or surgery may be needed in extreme/serious cases.

According to the global iron deficiency anaemia treatment market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Drug Type

• Ferrous Sulphate

• Ferrous Gluconate

• Ferrous Fumarate

• Ferric Hydroxide

• Sodium Ferric Gluconate

• Iron Carbohydrates

• Others

Market Breakup by Route of Administration

• Tablets

• Capsules

• Liquids

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increasing Prevalence, Rising Investment for Healthcare Infrastructure, Increasing Research and Development Activities to be the Key Market Trends

The growth of the iron deficiency anaemia treatment market is primarily driven by the rising prevalence of the disease as well as chronic kidney diseases. The market is also propelled by other factors such as the rapidly developing healthcare infrastructure.

The growth of the market can also be attributed to the rising awareness about the disease as well as its treatment by the public and private organisations.

Rising disposable incomes of the populations and the increased risk of blood dilution will also increase the demand for iron deficiency anaemia treatments. As the population ages and people lead sedentary lifestyles, the market is expected to grow further in the coming years.

The market is also witnessing rapid growth due to the increasing research and development activities. As a result, the market is expected to grow significantly over the next few years.

In addition, the approval and launch of more drugs is expected to accelerate the market growth. Rising investment in advanced technology and growth in emerging markets will act as lucrative opportunities for the growth of the iron deficiency anaemia treatment market in the coming years.

Factors like High Costs of the Treatment and Lack of Professionals are Restricting the Growth of the Market

The high cost of the treatment will hamper the growth of the market as most of the patients are unable to afford it. In the developing countries, iron deficiency anaemia treatment market will be challenged by a lack of skilled professionals and medical infrastructure.

North America Dominates the Global Iron Deficiency Anaemia Treatment Market

North America dominates the iron deficiency anaemia treatment market due to the region's well-established healthcare infrastructure. The key players will be increasingly interested in new technologies, which will add further growth to the market.

It is expected that the Asia Pacific region will also witness significant growth over the forecast period due to population growth and rise in healthcare spending.

Therapeutic Landscape

It is common for IDA patients to be prescribed oral iron supplements in pill, tablet, or syrup form in the early stages. There are several over the counter (OTC) iron remedies available in the market. The gastrointestinal side effects of oral iron reduce patient compliance. It is recommended to use intravenous iron if the patient no longer responds to these drugs or if the drugs are not working as effectively as before.

IDA Approved Drugs

Auryxia (Riona/ KRX-0502/Ferric Citrate): Akebia Therapeutics

Due to its unique chemical properties and mechanism of action, Auryxia is a calcium-free iron-based compound that doubles as a treatment for CKD patients. This drug contains a small molecule called ferric citrate as its active ingredient.

Immediately following its approval by the US Food and Drug Administration (FDA) in September 2014, the drug was marketed in the United States as a phosphate binder for hyperphosphatemia. It was approved by the FDA in 2017 for IDA, a second indication for treatment of adult patients.

Feraccru/Accrufer (Ferric Maltol/ ST10): Shield Therapeutics

Feraccru/Accrufer provides an alternative to intravenous iron therapy for patients who are intolerant to oral iron supplements.

Feraheme/Rienso (Ferumoxytol): AMAG Pharmaceuticals

For intravenous use, Feraheme contains ferumoxytol as a replacement for iron. It is an inorganic magnetite (superparamagnetic iron oxide) coated with polyglucose sorbitol carboxymethyl ether.

Clinical Trials

IDA Emerging Drugs

MPB-1514 (IOP Injection): MegaPro Biomedical

MegaPro Biomedical is developing MPB-1514/IOP injection for the treatment of IDA that is sugar-free. It is extremely safe as it follows doctor's prescription. The PEG coating would allow high-dose administration and lead to an increase in red blood cells without frequent injections. Currently, the drug is the only sugar-free injection in development.

IDAX (IHAT-02): Nemysis

Nemysis (IHAT-02/IDAX) is the first ferritin-mimic product that uses a tartrate salt to insulate the ferrihydrite nanocore of adipate-buffered ferritin. IHAT is well absorbed and maintains healthy gut bacteria. IHAT has been shown to be efficiently absorbed by humans and correct markers of iron deficiency without causing gastrointestinal side effects. As a result of this product, iron can be absorbed in the intestine in a manner similar to what happens naturally.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global iron deficiency anaemia treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Amgen Inc.

• Hoffmann-La Roche Ltd

• Novartis AG

• Pfizer Inc

• Janssen Pharmaceuticals, Inc.

• AMAG Pharmaceuticals

• Teva Pharmaceutical Industries Ltd.

Key Highlights of the Report